Comparison of the ENDOCUFF VISION® Endoscopy Cap Coupled With GI GENIUS™ Artificial Intelligence Compared to Each Device Alone in Improving Colonic Adenoma Detection Rate During Colonoscopy

Colorectal Cancer Clinical Trial

— COLODETECT2  

Official title:

Comparison of the ENDOCUFF VISION® Endoscopy Cap Coupled With GI GENIUS™ Artificial Intelligence Compared to Each Device Alone in Improving Colonic Adenoma Detection Rate During Colonoscopy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05594576
• Other study ID #: NIMAO/2021-2/LC-01
• Status: Recruiting
• Phase: N/A
• Start date: October 18, 2022
• Est. completion date: November 2024

Study information

• Verified date: February 2024
• Source: Centre Hospitalier Universitaire de Nimes
• Contact: Ludovic Caillo
• Phone: 04.66.68.37.94
• Email: ludovic.caillo[@]chu-nimes.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Colorectal cancer is the 2nd most common cause of death by cancer. Screening is therefore essential, with a positive impact for prevention, and in the visualization and removal of colonic adenomas, pre-cancerous lesions of colorectal cancer. The colonic adenoma detection rate (CADR), the gold standard for colonoscopy screening and screening studies, is the ratio of the number of colonoscopies with at least one histologically verified colonic adenoma to the total number of colonoscopies performed in a center. It varies between 25 and 45% depending on the center. There is a large inter-operator CADR variability, which has been linked to an increased incidence and excess mortality in colorectal cancers. To improve this detection rate, several innovative techniques have been developed: The endoscopic cap helps improve this detection rate: it is a 2cm tip with double row of plastic wings, fixed to the distal end of the colonoscope, which acts by unfolding the colonic haustrations allowing a better visualization of adenomas, and more particularly those of sessile morphology and sigmoidal location. Several multicenter studies have shown an improvement in the adenoma detection rate with this device compared to screening colonoscopy alone, with an adenoma detection rate optimization of 14%. Since then other devices, such as the Endocuff, have emerged with comparable efficacy. The Medtronic© GI GENIUS system integrates artificial intelligence (AI) to assist in the detection of polyps. It automatically identifies these precancerous lesions in real time. The study investigators previously performed a retrospective pilot study (COLODETECT), comparing colonoscopy alone as a control group, against AI alone and against the combined cap + AI. This study showed encouraging results in terms of colonic adenoma detection rate (60% for the AI + cap group versus 37% for the AI alone group versus 33% for the colonoscopy alone group, p=0.037) However, it requires a higher level of evidence to be validated in practice. This prospective COLODETECT2 study estimated an a priori expected difference between A.I. - Cap and A.I. alone of about 15% CADR. The GI GENIUS artificial intelligence system and the ENDOCUFF VISION endoscopic cap have separately proven their effectiveness in terms of colonic adenoma detection compared to colonoscopy alone. However, some limitations remain: existence of false positives (mucosal folds, residues), some morphological types still difficult to recognize (scalloped adenomas), non visualized colonic lesions. This study therefore focuses on the possible complementarity of these 2 medical devices, in order to maximize the detection rate of colonic adenomas, and thus overcome the limitations of these two techniques by optimizing the visualization of these precancerous lesions, and consequently increasing the impact of colorectal cancer screening. The study authors hypothesize that the combination of GI GENIUS™ AI coupled with the ENDOCUFF VISION® endoscopy cap provides a better colonic adenoma detection rate (CAD) during colonoscopy than either GI GENIUS™ AI alone or the ENDOCUFF VISION® cap alone.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 483
• Est. completion date: November 2024
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Need to perform colorectal cancer screening colonoscopy:
• Primary Screening: Fecal Immunological Test positive;
• Secondary screening: personal or family history of polyps, personal or family history of colorectal cancer, rectorrhagia-like symptomatology.
• Patient candidate for outpatient management.
• Patient who has given free and informed consent.
• Patient who has signed the consent form.
• Patient affiliated or beneficiary of a health insurance plan.

Exclusion Criteria:

• The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
• The subject refuses to sign the consent
• It is impossible to give the subject informed information
• The patient is under safeguard of justice or state guardianship
• History of inflammatory bowel disease, Crohn's disease.
• Failure of a previous colonoscopy.
• Known familial polyposis.
• Contraindication to polypectomy (coagulation disorder, treatment with CLOPIDOGREL / anticoagulant).

Related Conditions & MeSH terms

• Adenoma
• Colorectal Cancer
• Intestinal Polyps

Intervention

Procedure:
• GI GENIUS™ artificial intelligence system
Device used during coloscopy for detection of colonic adenoma
• ENDOCUFF VISION® endoscopic cap
Device used during coloscopy for detection of colonic adenoma

Locations

Country	Name	City	State
France	CHU de Limoges	Limoges
France	CHU de Nîmes	Nîmes

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nimes	University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare colonic adenoma detection rates (CADR) during colonoscopy between the three groups	%; defined as the number of colonoscopies with detection of at least one colonic adenoma out of the total number of colonoscopies performed	Day 0
Secondary	Operator effect on CADR, between the three groups, per operator	CADR (%), defined as the number of colonoscopies with detection of at least one colonic adenoma out of the total number of colonoscopies performed for each strategy per operator	Day 0
Secondary	CADR according to adenoma size, for each strategy	CADR (%), detected by colonoscopy according to their size in mm (especially those smaller than 3 mm)	Day 0
Secondary	CADR according to adenoma histology for each strategy.	CADR (%), detected by colonoscopy according to histology (low/high grade dysplasia)	Day 0
Secondary	CADR according to adenoma morphology for each strategy.	CADR (%), detected by colonoscopy according to (Paris morphological classification: Ip, Is, IIa, IIb, IIc, III)	Day 0
Secondary	Shrinkage time for the Genius groups.	Measurement of withdrawal time (min, sec) for GI GENIUS™-Cap software or GI GENIUS™ software alone strategies (time from cecum to colonoscope removal).	Day 0
Secondary	Rate of cecal intubation between groups	% of exams in which the entire colon was examined.	Day 0
Secondary	Progression time between groups	Mean progression time (time from introduction of colonoscope to cecum; min, sec	Day 0
Secondary	Operative time between groups	Mean time from introduction of colonoscope to removal of endoscope from patient; min, sec	Day 0
Secondary	The number of immediate intra- and postoperative adverse events (bleeding, perforation) according to the different strategies	Collection of immediate intra- and postoperative adverse events (bleeding, perforation) for the three study strategies	Day 0